NO20020837L - Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer - Google Patents

Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer

Info

Publication number
NO20020837L
NO20020837L NO20020837A NO20020837A NO20020837L NO 20020837 L NO20020837 L NO 20020837L NO 20020837 A NO20020837 A NO 20020837A NO 20020837 A NO20020837 A NO 20020837A NO 20020837 L NO20020837 L NO 20020837L
Authority
NO
Norway
Prior art keywords
identifying
substance
human prostaglandin
respect
properties
Prior art date
Application number
NO20020837A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020837D0 (no
Inventor
Hiroyuki Hirai
Kazuyuki Ogawa
Kinya Nagata
Syoichi Takano
Original Assignee
Bml Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bml Inc filed Critical Bml Inc
Publication of NO20020837D0 publication Critical patent/NO20020837D0/no
Publication of NO20020837L publication Critical patent/NO20020837L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
NO20020837A 1999-08-23 2002-02-20 Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer NO20020837L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23620799 1999-08-23
JP2000153172 2000-05-24
PCT/JP2000/005615 WO2001014882A1 (fr) 1999-08-23 2000-08-22 Identification des proprietes d'une substance pour les recepteurs de prostaglandine d

Publications (2)

Publication Number Publication Date
NO20020837D0 NO20020837D0 (no) 2002-02-20
NO20020837L true NO20020837L (no) 2002-04-22

Family

ID=26532542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020837A NO20020837L (no) 1999-08-23 2002-02-20 Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer

Country Status (9)

Country Link
US (1) US6884593B1 (de)
EP (1) EP1211513B1 (de)
JP (1) JP3486408B2 (de)
AT (1) ATE315230T1 (de)
AU (1) AU772121B2 (de)
CA (1) CA2383135C (de)
DE (2) DE1211513T1 (de)
NO (1) NO20020837L (de)
WO (1) WO2001014882A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US20030096783A1 (en) * 2001-10-10 2003-05-22 Millennium Pharmaceuticals, Inc. 21132, a human G-protein coupled receptor family member and uses therefor
AU2003231513A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
EP2423190A1 (de) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. PGD-2-Rezetorantagonismus aufweisende Verbindungen
ZA200505523B (en) 2002-12-20 2006-09-27 Amgen Inc Asthma and allergic inflammation modulators
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
AU2005229356B2 (en) 2004-03-11 2011-06-09 Idorsia Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
MXPA06011891A (es) * 2004-04-20 2007-04-24 Pfizer Metodo para tratar el dolor neuropatico.
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
JP5208510B2 (ja) 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
US7999119B2 (en) 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009061676A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
WO2009061681A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc Antagonists of pgd2 receptors
ES2471919T3 (es) 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
AU2009204700B2 (en) 2008-01-18 2013-07-04 Atopix Therapeutics Limited Compounds having CRTH2 antagonist activity
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
CN101952244B (zh) 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
UA98839C2 (en) * 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2257536A4 (de) * 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Cyclische diarylether als antagonisten von prostaglandin-d2-rezeptoren
JP2011513242A (ja) * 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
WO2009145989A2 (en) * 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
EP2307362A4 (de) 2008-07-03 2012-05-09 Panmira Pharmaceuticals Llc Antagonisten der prostaglandin-d2-rezeptoren
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
CN102596902A (zh) * 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
CA2782085A1 (en) 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (de) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Beurteilung von präeklampsie unter verwendung von tests für freien und dissoziierten plazentalen wachstumsfaktor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040426A (en) * 1996-06-05 2000-03-21 Bml, Inc. Human Th2 specific protein
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2

Also Published As

Publication number Publication date
DE60025368D1 (de) 2006-03-30
EP1211513A1 (de) 2002-06-05
AU772121B2 (en) 2004-04-08
ATE315230T1 (de) 2006-02-15
DE1211513T1 (de) 2002-11-14
EP1211513A4 (de) 2003-04-16
WO2001014882A1 (fr) 2001-03-01
NO20020837D0 (no) 2002-02-20
CA2383135C (en) 2010-11-30
US6884593B1 (en) 2005-04-26
DE60025368T2 (de) 2006-09-14
CA2383135A1 (en) 2001-03-01
AU6598800A (en) 2001-03-19
JP3486408B2 (ja) 2004-01-13
EP1211513B1 (de) 2006-01-04

Similar Documents

Publication Publication Date Title
NO20020837L (no) Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
NO983431L (no) Anti-klöemidler
PT1235787E (pt) Receptores agonistas beta2 adrenergicos
ATE439861T1 (de) Verfahren zur modulierung von cd200-rezeptoren
ATE369848T1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
EP1017713A4 (de) ZYKLISCHE AGONISTEN UND ANTAGONISTEN DER C5a REZEPTOREN SOWIE G-PROTEIN GEKOPPELTEN REZEPTOREN
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
NO20010446L (no) Substituert anilidforbindelser og metoder
NO327163B1 (no) Loselige reseptorer og ligandantistoffer for behandling av immunologisk sykdom
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
HUT77631A (hu) Eljárás a levobupivakain és származékai rezolválására
ATE210984T1 (de) Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ES2162936T3 (es) Tratamiento de la ansiedad.
ATE432350T1 (de) G-protein gekoppelte rezeptoren
BG102064A (en) Method for increasing the retinal blood circulation
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
BR0012921A (pt) Compostos calcilìticos
ES2104509B1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
EA200100182A1 (ru) Лечение состояний тревожности
EA199700297A1 (ru) Новый способ борьбы с насекомыми
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
UA39967C2 (uk) Спосіб вимірювання параметрів нвч- сигналів та трактів
MY128351A (en) ß2-ADRENERGIC RECEPTOR AGONISTS